Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:4
  • preuzimanja u poslednjih 30 dana:0

Sadržaj

članak: 2 od 14  
Back povratak na rezultate
2017, vol. 74, br. 2, str. 167-172
Farmakovigilanca kao imperativ moderne medicine - iskustvo iz Crne Gore
Agency for Medicines and Medical Devices of Montenegro, Podgorica, Montenegro
Sažetak
(ne postoji na srpskom)
Reporting on ADRs by healthcare workers should be a part of everyday clinical practice, since it is one of the indicators of healthcare quality. National ADR reporting system in Montenegro is organised by the Pharmacovigilance Department of the Agency for Medicines and Medical Devices of Montenegro, but the number of reports coming from healthcare professionals is quite low. Therefore, it is necessary to conduct additional training of healthcare workers, to improve their awareness about the importance of ADRs and the risk factors that lead to them, as well as to increase the number of reported suspected ADRs.
Reference
*** Safety of medicines: A guide to detecting and reporting adverse drug reactions - why health professionals need to take action: Why pharmacovigilance is needed in every country. http://apps.who.int/medicinedocs/en/d/Jh2992e/5.html
*** (2011) Regulation: Low of drugs. Official Register of Montenegro, no 56, http://www.s1uzbeni1ist.me/PravniAktDetalji.aspx?tag=%7BEB8D380A-167D-4B1B-BFBB-B6593034D628%7D, (Montenegrian)
*** (2014) Annual report - servlet1. http://www.calims.me/Portal/faces/servlet1?afrWindowMode=0&putanja=Izvje%C5%A1taj+o+prijavljenim+ne%C5%BEeljenim+dejstvima+za+2014.+godinu.pdf&afrLoop=16645829555640651&adf.ctrl-state=tgt7xozzi38 (Mon
*** (2013) Annual report - servlet1. http://www.calims.me/Portal/faces/servlet1?putanja=Izvjestaj+o+prijavljenim+nezeljenim+dejstvima.+za+2013+godinu.pdf&afrWindowMode=0&afrLoop=16733522002965960&adf.ctrl-state=1d37e0oggc38 (Montenegrian
*** Safety monitoring of medicinal products: Guidelines for setting up and running a Pharmacovigilance center. u: Reporting: 5.3 Under-reporting, http://apps.who.int/medicinedocs/en/d/Jh2934e/6.3.html, 5. Special Issues
*** (2014) Report on adverse drug reactions. http://www.halmed.hr/pdf/publikacije/Izvjesce_o_nuspojavama_u_2014.pdf, (Croatian)
*** (2010) Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance. http://ec.europa.eu/health/files/eudralex/vol-1/dir_2010_84/dir_2010_84_en.pdf
*** Drug reactions database. http://www.adr-database.com/WhatareADRs.html
ALIMS (2013) Godisnji izvestaj NRL. http://www.alims.gov.rs/ciril/files/2014/12/NDL-2013.pdf (Montenegrian)
Bates, D. W. (1995) Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA: The Journal of the American Medical Association, 274(1): 29-34
Bates, D.W., Leape, L.L., Petrycki, S. (1993) Incidence and preventability of adverse drug events in hospitalized adults. Journal of General Internal Medicine, 8(6): 289-294
CALIMS Letters to health care workers. https://www.calims.me/, (Montenegrian)
Chyka, P.A. (2000) How many deaths occur annually from adverse drug reactions in the united states?. American Journal of Medicine, 109(2): 122-130
Classen, D.C. (1991) Computerized Surveillance of Adverse Drug Events in Hospital Patients. JAMA: The Journal of the American Medical Association, 266(20): 2847
Dormann, H., Muth-Selbach, U., Krebs, S., Criegee-Rieck, M., Tegeder, I., Schneider, H. T., Hahn, E.G., Levy, M., Brune, K., Geisslinger, G. (2000) Incidence and Costs of Adverse Drug Reactions During Hospitalisation. Drug Safety, 22(2): 161-169
Dukes, M.N. (1996) Mayler's side effects of drugs. Amsterdam: Elsevier
Düsing, R. (2006) Overcoming barriers to effective blood pressure control in patients with hypertension. Current Medical Research and Opinion, 22(8): 1545-1553
European Medicine Agency (2012) Setting the scene: new European Union Pharmacovigilance legislation. Vienna: Agencies of the European Union
European Medicines Agency Human medicines: Short-acting beta-agonists. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Short-acting_beta-agonists/human_referral_prac_000013.jsp&mid=WC0b01ac05805c516f
European Medicines Agency PRAC - PRAC: Agendas, minutes and highlights. http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/document_listing/document_listing_000353.jsp&mid=WC0b01ac05805a21cf
Francis, G.S. (1999) Cardiac complications in the intensive care unit. Clinics in Chest Medicine, 20(2): 269-285
Gurwitz, J.H., Field, T.S., Avorn, J., McCormick, D., Jain, S., Eckler, M., Benser, M., Edmondson, A.C., Bates, D.W. (2000) Incidence and preventability of adverse drug events in nursing homes. American Journal of Medicine, 109(2): 87-94
Gurwitz, J.H., Field, T.S., Harrold, L.R., Rothschild, J., Debellis, K., Seger, A.C., Cadoret, C., Fish, L.S., Garber, L., Kelleher, M., Bates, D.W. (2003) Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA, 289(9): 1107-16
Hallas, J., Gram, L., Grodum, E., Damsbo, N., Brosen, K., Haghfelt, T., Harvald, B., Beck-, N.J., Worm, J., Jensen, K., i dr. (2012) Drug related admissions to medical wards: a population based survey. British Journal of Clinical Pharmacology, 33(1): 61-68
Hallas, J., Harvald, B., Gram, L. F., Grodum, E., Brøsen, K., Haghfelt, T., Damsbo, N. (1990) Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. Journal of Internal Medicine, 228(2): 83-90
Impicciatore, P., Choonara, I., Clarkson, A., Provasi, D., Pandolfini, C., Bonati, M. (2001) Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. British Journal of Clinical Pharmacology, 52(1): 77-83
Jelenkovic, A. (2002) Adverse drug reactions. Belgrade: Hellen J, Serbian
Johnson, J.A. (1995) Drug-Related Morbidity and Mortality. Archives of Internal Medicine, 155(18): 1949
Lazarou, J., Pomeranz, B.H., Corey, P.N. (1998) Incidence of Adverse Drug Reactions in Hospitalized Patients. JAMA, 279(15): 1200
Levy, M., Azaz-Livshits, T., Sadan, B., Shalit, M., Geisslinger, G., Brune, K. (1999) Computerized surveillance of adverse drug reactions in hospital: Implementation. European Journal of Clinical Pharmacology, 54(11): 887-892
Malgarini, R.B., Pimpinella, G. (2000) Thrombotic Thrombocytopenic Purpura Induced by Ticlopidine: The Power of “Dear Health Professional” Letters. Annals of Pharmacotherapy, 34(3): 404-405
Martínez-Mir, I., García-López, M., Palop, V., Ferrer, J. M., Estañ, L., Rubio, E., Morales-Olivas, F. J. (2003) A prospective study of adverse drug reactions as a cause of admission to a paediatric hospital. British Journal of Clinical Pharmacology, 42(3): 319-324
Moore, N., Lecointre, D., Noblet, C., Mabille, M. (2002) Frequency and cost of serious adverse drug reactions in a department of general medicine. British Journal of Clinical Pharmacology, 45(3): 301-308
Mugoša, S., Bukumirić, Z., Kovačević, A., Bošković, A., Protić, D., Todorović, Z. (2015) Adverse drug reactions in hospitalized cardiac patients: Characteristics and risk factors. Vojnosanitetski pregled, vol. 72, br. 11, str. 975-981
Nelson, K.M., Talbert, R.L. (1996) Drug-related hospital admissions. Pharmacotherapy, 16(4); 701-707
Olivier, P., Boulb??s, O., Tubery, M., Lauque, D., Montastruc, J., Lapeyre-Mestre, M. (2002) Assessing the Feasibility of Using an Adverse Drug Reaction Preventability Scale in Clinical Practice. Drug Safety, 25(14): 1035-1044
Peyriere, H., Cassan, S., Floutard, E., Riviere, S., Blayac, J., Hillaire-Buys, D., le Quellec, A., Hansel, S. (2003) Adverse Drug Events Associated with Hospital Admission. Annals of Pharmacotherapy, 37(1): 5-11
Pirmohamed, M., James, S., Meakin, S., Green, C., i dr. (2004) Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18820 patients. BMJ, 329: 15
Pushkin, R., Frassetto, L., Tsourounis, C., Segal, E.S., Kim, S. (2010) Improving the Reporting of Adverse Drug Reactions in the Hospital Setting. Postgraduate Medicine, 122(6): 154-164
Qureshi, Z.P., Seoane-Vazquez, E., Rodriguez-Monguio, R., Stevenson, K.B., Szeinbach, S.L. (2011) Market withdrawal of new molecular entities approved in the United States from 1980 to 2009. Pharmacoepidemiology and Drug Safety, 20(7): 772-777
Smith, C. C., Bennett, P. M., Pearce, H. M., Harrison, P. I., Reynolds, D. J. M., Aronson, J. K., Grahame-Smith, D. G. (2003) Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. British Journal of Clinical Pharmacology, 42(4): 423-429
Thürmann, P.A. (2001) Methods and systems to detect adverse drug reactions in hospitals. Drug Saf, 24(13); 961-8
Todorović, Z., Prostran, M.J., Janković, S. (2009) Pharmacovigilance. u: Prostran M.; Stanulović M.; Marisavljern D.; Đurić D. [ur.] Pharmaceutical medicine, Vršac: Hemofarm AD, Serbian, p. 467-516
Uppsala Monitoring Centre http://www.who-umc.org/, 2014 September 26
Uppsala Monitoring Centre Reporting trends. http://who-umc.org/DynPage.aspx?id=108476&mn1=7347&mn2=7252&mn3=7322&mn4=7558
Varenhorst, C., James, S., Erlinge, D., Brandt, J. T., Braun, O. O., Man, M., Siegbahn, A., Walker, J., Wallentin, L., Winters, K. J., Close, S. L. (2009) Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. European Heart Journal, 30(14): 1744-1752
WHO (2002) The importance of pharmacovigilance: Safety monitoring of medicinal products. http://apps.who.int/medicinedocs/pdf/s4893e/s4893e.pdf
 

O članku

jezik rada: engleski
vrsta rada: aktuelni problemi
DOI: 10.2298/VSP150428167M
objavljen u SCIndeksu: 09.02.2017.
metod recenzije: dvostruko anoniman
Creative Commons License 4.0

Povezani članci

Vojnosanitetski pregled (2015)
Neželjena dejstva lekova kod hospitalizovanih kardioloških bolesnika - karakteristike i faktori rizika
Mugoša Snežana, i dr.

Vojnosanitetski pregled (2021)
Neželjena dejstva sunitiniba - karakteristike i faktori rizika
Mugoša Snežana, i dr.

Hosp Pharm Int Multi J (2015)
Farmakovigilanca - podsticaj zdravstvenim radnicima
Mugoša Snežana S., i dr.

prikaži sve [7]